MedTrace Logo

Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient

NCT05936346 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-01-23

No results posted yet for this study

Summary

Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.

Conditions

  • Aging

Interventions

DIETARY_SUPPLEMENT

Salvia haenkei 175mg

The product appears as a soft gel containing the dry extract of Salvia haenkei

DIETARY_SUPPLEMENT

Salvia haenkei 350mg

The product appears as a soft gel containing the dry extract of Salvia haenkei

Sponsors & Collaborators

  • IBSA Farmaceutici Italia Srl

    lead INDUSTRY

Principal Investigators

  • Roberta Noseda, MD, PhD · Istituto di Scienze Farmacologiche della Svizzera Italiana, Lugano (Switzerland)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-17
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936346 on ClinicalTrials.gov